Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed the day trading at $6.34 up 7.28% from the previous closing price of $5.91. In other words, the price has increased by $+0.43 from its previous closing price. On the day, 3211697 shares were traded. AMRX stock price reached its highest trading level at $6.46 during the session, while it also had its lowest trading level at $5.78.
Ratios:
For a better understanding of AMRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.74. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.91. In the meantime, Its Debt-to-Equity ratio is 8.48 whereas as Long-Term Debt/Eq ratio is at 8.11.
On March 08, 2021, Goldman Upgraded its rating to Buy which previously was Sell and also upped its target price recommendation from $4 to $6.50.
Guggenheim Upgraded its Neutral to Buy on December 14, 2020, while the target price for the stock was maintained at $5.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’23 when BOYER ANDREW S sold 29,302 shares for $4.13 per share. The transaction valued at 120,921 led to the insider holds 244,739 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 1.81B and an Enterprise Value of 4.47B. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 100.16, and their Forward P/E ratio for the next fiscal year is 9.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.82 while its Price-to-Book (P/B) ratio in mrq is 2.96. Its current Enterprise Value per Revenue stands at 1.87 whereas that against EBITDA is 11.19.
Stock Price History:
Over the past 52 weeks, AMRX has reached a high of $6.30, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is 5.56, while the 200-Day Moving Average is calculated to be 4.36.
Shares Statistics:
Over the past 3-months, AMRX traded about 1.44M shares per day on average, while over the past 10 days, AMRX traded about 1.46M shares per day. A total of 306.56M shares are outstanding, with a floating share count of 109.87M. Insiders hold about 64.21% of the company’s shares, while institutions hold 24.75% stake in the company. Shares short for AMRX as of Feb 29, 2024 were 1.83M with a Short Ratio of 1.27, compared to 2.54M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.60% and a Short% of Float of 0.67%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of $0.09 for the current quarter, with a high estimate of $0.11 and a low estimate of $0.08, while EPS last year was $0.12. The consensus estimate for the next quarter is $0.13, with high estimates of $0.15 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.63 and $0.53 for the fiscal current year, implying an average EPS of $0.57. EPS for the following year is $0.64, with 4 analysts recommending between $0.7 and $0.54.
Revenue Estimates
3 analysts predict $620.36M in revenue for the current quarter. It ranges from a high estimate of $631.33M to a low estimate of $606.75M. As of the current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $557.54M, an estimated increase of 11.30% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $653.16M, an increase of 9.00% less than the figure of $11.30% in the same quarter last year. There is a high estimate of $655M for the next quarter, whereas the lowest estimate is $650.19M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $2.63B, while the lowest revenue estimate was $2.59B, resulting in an average revenue estimate of $2.61B. In the same quarter a year ago, actual revenue was $2.39B, up 9.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $2.71B in the next fiscal year. The high estimate is $2.75B and the low estimate is $2.62B. The average revenue growth estimate for next year is up 3.80% from the average revenue estimate for this year.
